Cerevel Therapeutics (CERE)
(Delayed Data from NSDQ)
$42.24 USD
+0.18 (0.43%)
Updated May 14, 2024 04:00 PM ET
After-Market: $42.20 -0.04 (-0.09%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Brokerage Reports
Cerevel Therapeutics Holdings, Inc. [CERE]
Reports for Purchase
Showing records 1 - 17 ( 17 total )
Company: Cerevel Therapeutics Holdings, Inc.
Industry: Unclassified
Company: Cerevel Therapeutics Holdings, Inc.
Industry: Unclassified
Optimized Entry and Exit Levels for CERE 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cerevel Therapeutics Holdings, Inc.
Industry: Unclassified
Company: Cerevel Therapeutics Holdings, Inc.
Industry: Unclassified
Despite More Delays, Next Year Remains Catalyst-Rich; Reit. Buy; Adjusted PT to $41
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Cerevel Therapeutics Holdings, Inc.
Industry: Unclassified
Switching Things Up Ahead of Seven Data Readouts; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Cerevel Therapeutics Holdings, Inc.
Industry: Unclassified
Takeaways From Our Conversation With Cerevel Therapeutics Chief Scientific Officer
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Cerevel Therapeutics Holdings, Inc.
Industry: Unclassified
Good Things Come to Those Who Wait; Reiterate Buy; PT Adjusted to $45
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Cerevel Therapeutics Holdings, Inc.
Industry: Unclassified
Cerevel Rules Out Pressor Effect For Chronic Dosing with Emraclidine; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Cerevel Therapeutics Holdings, Inc.
Industry: Unclassified
Modest Delays But Core Element of Thesis Intact; Reiterate Buy; PT Down to $48
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Cerevel Therapeutics Holdings, Inc.
Industry: Unclassified
Pipeline Continues to Add Depth and Breadth; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Cerevel Therapeutics Holdings, Inc.
Industry: Unclassified
Pipeline Breadth and Depth Remains Compelling; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Cerevel Therapeutics Holdings, Inc.
Industry: Unclassified
Quiet 4Q21 Call Following Big Emraclidine and Darigibat Updates Earlier This Year; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Cerevel Therapeutics Holdings, Inc.
Industry: Unclassified
Darigibat Shows Powerful Signal in Phase 1 Anxiety Model and Development to Continue in Anxiety Disorders; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Cerevel Therapeutics Holdings, Inc.
Industry: Unclassified
Cerevel Provides Pipeline Update With 231 (Emraclidine) Phase 2 Program to Initiate in Mid-2022
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Cerevel Therapeutics Holdings, Inc.
Industry: Unclassified
Company: Cerevel Therapeutics Holdings, Inc.
Industry: Unclassified
Biotech''s "Supply Chain" Issue - Impacts to Catalysts, Clinical Development
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Cerevel Therapeutics Holdings, Inc.
Industry: Unclassified
|